Jacobson and JBM announce factory license agreements

Jacobson Pharma Corporation Limited and JBM (Healthcare) Limited announced new license agreements involving Europharm, a Jacobson subsidiary, and Europharm HK and LCSTH, both JBM subsidiaries. The 2025 Europharm License Agreement, effective December 1, 2025, to January 27, 2028, grants Europharm HK use of 2,415 square meters of factory space for a monthly license fee of HK$247,000. This is regarded as an asset acquisition for JBM, with a right-of-use asset value estimated at HK$6,190,000.

Additionally, Europharm granted LCSTH a license for 2,072 square meters of factory space from January 28, 2025, to January 27, 2028, at a monthly fee of HK$218,000. The aggregate annual license fees receivable by Jacobson for both agreements are subject to annual caps of HK$5,580,000 for the financial years ending March 31, 2026, and March 31, 2027, and HK$4,590,000 for the period ending January 27, 2028.

These transactions are subject to reporting and announcement requirements under Listing Rules due to their connected nature, with Mr. Sum Kwong Yip, Derek, holding controlling interests in both companies. However, they are exempt from circular and independent shareholders' approval requirements as applicable percentage ratios are below 5%.